

8

AB1 - 0628

INVC.....

**MOLECULAR DETECTION OF  
HUMAN HERPESVIRUS-6 IN CANCER**

by

**ANIL CHANDRASHEKRAN, B.Sc (Hons)**

**A dissertation submitted in partial fulfilment of the  
requirements for the Degree of Master of Science.**

**PERPUSTAKAAN UNIVERSITI MALAYA**

**Department of Genetics and Cellular Biology  
Faculty of Science , University of Malaya,  
Kuala Lumpur.**

**January 1995**

14.06.2000  
Dimikrofilkan pada.....  
No. Mikrofilis.....  
Jumlah Mikrofilis.....

Perpustakaan Universiti Malaya



HAMSIH BT. MOHAMAD ZAHARI  
UNIT REPROGRAFI  
PERPUSTAKAAN UTAMA  
UNIVERSITI MALAYA

## **Abstract**

Human Herpesvirus-6 (HHV-6) is ubiquitous in human populations and is the causative agent for exanthem subitum. Primary infection occurs in CD4 T lymphocytes and it is cytopathic in the productive phase of infection. The virus is pleiotropic for several established cell lines including T and B lymphocytes, macrophages and neural cells.

The primary objective of the study was to determine the frequency of HHV-6 DNA sequences in tissue specimens from leukemia and lymphoma, premalignant and malignant oral lesions and cervical carcinoma patients. From this study, DNA was successfully extracted from fresh blood, fresh frozen tissue and archival (formalin fixed) tissue. DNA obtained were from leukemia, oral carcinoma and cervical carcinoma. These DNA were successfully amplified using the Polymerase Chain Reaction (PCR) method for the detection of HHV-6. It has also been observed that a nested PCR protocol was more sensitive in the detection of low copy numbers of HHV-6 DNA. PCR has thus been shown to be useful in HHV-6 viral diagnosis in various types of cancer. Furthermore, a non-radioactive method of detecting amplified products has been optimized and has been found to be advantageous with respect to potential hazards, ease of labelling and long term storage when compared to traditional radioactive methods of probe labelling and hybridization.

Analysis of DNA extracted from leukemia with PCR showed that 3/41 (7.3%) were positive for HHV-6 with outer primers and 16/41 (39.0%) with nested primers. All the 16 nested amplicons hybridized to a digoxigenin labelled HHV-6 specific oligonucleotide. Using another set of primers (A and B) it was noted that 10/41 (24.3%) were positive and all 10 (24.3%) hybridized to another digoxigenin labelled HHV-6 specific

oligonucleotide probe. This suggests that the HHV-6 DNA was present in low copy number and hence the efficiency of detection in nested PCR. Previous data shows high seroprevalence of HHV-6 in leukemia patients, indicative of reactivation of the virus in those patients but the overall low frequency of DNA in the transformed cells suggests that the virus was reactivated independently.

No amplification of HHV-6 DNA sequence was observed with outer primers in 5 lymphoma patients but upon nesting, 1 (20.0%) patient's DNA was positive but with another set of primers(AandB) 2 (40.0%) samples were positive. All 3 samples hybridized with the appropriate probes. Our previous serological data showed that EBV but not HHV-6 was reactivated in lymphoma patients. Thus in these lymphomas the two viruses act independantly and the prevalence possibly suggests that the B-cell pools of cells are involved in EBV related lymphoma.

18 biopsy material of oral carcinoma of the buccal mucosa (fresh frozen tissue and archival tissue) were also obtained and analysed for HHV-6 DNA. Initial amplification with outer primers revealed 6 (33.3%) positive patients but upon nesting 11 (61.1%) patients were positive for HHV-6 DNA. The use of A and B primers in another PCR reaction showed 10 (55.5%) positive patients. All amplified products of both nested PCR and direct PCR hybridized specifically to the P2 and S, Dig labelled probe respectively. In addition, 23 (88.4%) out of 26 paraffin sections from buccal carcinomas stained immunohistochemically to a monoclonal antibody reactive to a late HHV-6 associated protein. The reaction was localized in the cytoplasm and nucleus of the malignant squamous epithelial cells. Control tissues did not react with the monoclonal antibody and antibody specificity was confirmed by virus adsorption studies. Moreover, it was noted that 3 (60.0%) out of 5 premalignant (leukoplakia and lichen planus) were positive for HHV-6 by nested PCR and PCR with

primer A and B. 4 (80.0%) of the samples were also reactive to the monoclonal antibody immunohistochemically.

Since the virus has been shown to have an oncogenic potential in *in vivo* studies, our observation, therefore suggest a possible cofactorial role for HHV-6 in the pathogenesis of oral carcinoma.

From the 19 samples of cervical carcinoma biopsies obtained, only 2 (10.5%) samples were positive by nested PCR to HHV-6 DNA. Both the amplified products hybridized to the P2 probe. No amplification nor hybridization was noted with primer A and B. Furthermore, no protein reactivity to a late HHV-6 associated protein immunohistochemically was noted in the 10 CIN3 and CIS samples obtained. These observations would strengthen the hypothesis that saliva which is present in the oral cavity may be important in the infection of oral epithelial cells.

Thus, like EBV, HHV-6, a ubiquitous virus with an apparent *in vitro* cytopathic activity, show dual tropism for lymphocytes and epithelial cells. Infection of the oral epithelial cells on the other hand may not be cytopathic to the host cell but may have a cofactorial role in the transformation towards the pathogenesis of oral carcinoma.



## ABSTRAK

Human Herpesvirus 6 (HHV-6) merupakan virus ubikuitos dalam populasi manusia dan adalah punca utama exanthem subitum. Infeksi primari adalah pada limfosit T CD 4 dan adalah sitopatik dalam fasa produktif infeksi.

Matlamat utama projek ini adalah untuk menentukan frekuensi DNA HHV-6 dalam spesimen tisu dari pesakit leukemia dan limfoma ,pra-kanser dan kanser mulut dan serviks. Dalam projek ini ,DNA dapat diekstrak dari pelbagai tisu termasuk darah, tisu segar, dan tisu terawet. DNA ini juga dapat diamplifikasi dengan teknik rantaian polimeras (PCR).PCR berganda (nested) didapati lebih berkesan untuk diagnosa infeksi HHV-6 dalam pelbagai jenis barah. Tambahan pula kaedah non-radioaktif untuk mengesan DNA yang diamplifikasikan dengan PCR dioptimakan dan juga berkelebihan dari aspek kesan bahaya, kesenangan melabel dan penyimpanan berbanding dengan kaedah tradisi radioaktif. Analisa DNA dari pesakit leukemia dengan PCR mendapat 3/41 (7.3%) positif untuk DNA HHV-6 dengan primer luar dan 16/41 (39.0%) dengan primer dalam. Kesemua 16 amplicon berhibridisasi kepada HHV-6 tertentu (Digoxigenin probe). Penggunaan set primer lain (A dan B) menghasilkan 10/41 (24.3%) positif dan kesemua amplicon juga berhibridisasi kepada HHV-6 tertentu digoxigenin probe lain. Keadaan ini mencadangkan bahawa DNA HHV-6 berada secara berbilang rendah dan menunjukkan keberkesanan PCR berbilang . Dari data seroprevalens dalam pesakit leukemia didapati tinggi dan juga menunjukkan reaktivasi virus tetapi frekuensi DNA yang rendah pula mencadangkan bahawa virus ini direaktivasi secara lain.

Tiada amplifikasi didapati untuk DNA HHV-6 dengan primer luar dalam 5 pesakit limfoma tetapi selepas PCR berganda (primer dalam) , 1 (20.0%) pesakit limfoma didapati positif untuk DNA HHV-6 . Dengan set primer lain (A dan B) pula , 2 (40.0%) sampel didapati positif. Ketiga - tiga sampel berhibridisasi kepada probe masing - masing.

Data serologi dulu mendapati bahawa EBV dan bukannya HHV-6 direaktivasikan dalam pesakit limfoma. Dengan ini, dalam pesakit limfoma, kedua-dua virus berinteraksi secara sendiri dan prevalens mencadangkan kumpulan sel B adalah berkaitan dengan limfoma EBV.

18 sampel barah dari rongga mulut khususnya bahagian pipi (termasuk sampel segar dan terawet) didapati dan dianalisa untuk DNA HHV-6. Amplifikasi dengan primer luar memberi 6 (33.3%) positif tetapi setelah PCR berganda 11 (61.1%), pesakit didapati positif untuk DNA HHV-

6. Pengguna set primer lain (A dan B) menunjukkan 10 (55.5%) pesakit yang positif. Kesemua produk amplifikasi hibridisasikan kepada prob masing-masing. Tambahan pula, 23 (88.4%) dari 26 sampel terawet barah mulut didapati positif dengan teknik imunokimia dengan penggunaan antibodi monoklonal yang spesifik untuk protin HHV-6. Reaksi didapati pada sitoplasma dan nukleus sel-sel malignan. Tisu-tisu kawalan tidak bereaksi dengan antibodi monoklonal dan penentuan antibodi monoklonal terbukti dengan penyerapan virus.

Didapati juga 3 (60.0%) dari 5 kes pra-malignan (leukoplakia dan liken planus) positif untuk DNA HHV-6 dengan PCR berganda dan set primer lain (A dan B). Empat (80.0%) daripada sampel ini bereaksi dengan antibodi monoklonal secara imunokimia.

Virus ini didapati mempunyai kesan onkogenik, pemerhatian dari projek ini mencadangkan salah satu punca secara kofaktor untuk HHV-6 dalam perkembangan barah mulut. Dari 19 kes karsinoma serviks, hanya 2 (10.5%) sampel didapati positif selepas PCR berganda untuk DNA HHV-6. Kedua-dua produk amplifikasi berhibridisasi kepada prob P2. Tiada amplifikasi atau hibridisasi didapati dengan set primer lain (A dan B). Tambahan pula tiada reaksi protin HHV-6 dalam sampel terawet pra-malignan atau karsinoma *in situ*. (CIN III/CIS) yang didapati secara imunokimia.

Pemerhatian di atas, menkukuhkan peranan air liur dalam rongga mulut sebagai faktor penting dalam infeksi sel-sel epitelial rongga mulut. Kini, HHV-6 seumpama EBV adalah virus ubikuitos mempunyai kesan sitopatik yang menunjukkan tropisma dual untuk sel-sel limfosit dan juga sel epitelial. Infeksi sel epitelial mulut mungkin tidak menghasilkan kesan sitopatik kepada sel hos tetapi, mungkin berperanan dalam transformasi sel ke arah perkembangan barah mulut.

## **Acknowledgement**

I would like to thank my supervisor, Prof .M. Yadav, for his guidance and support through this project. My sincere appreciation also goes to Dr.A. Norhanom, for having employed me as a research assistant under the Gynaecological Neoplasm project and for her support throughout this project. Thanks are due to Dr.R. Gallo (National Cancer Institute, U.S.A.) for the gift of the probe used in this study and to Dr. D. Ablashi (George Town University, U.S.A.) for the gift of the monoclonal antibody used. My gratitude is also extended to Prof. Vasudevan (Trichur Medical College, India). Dr. B.S. Tan (Institute for Medical Research, K.L.), Dr. Purushotoman (Kuala Lumpur General Hospital, K.L.), Dr.A. Aziz (Kuala Lumpur General Hospital, K.L.) for the cancer patient samples obtained for this study, and to Dr.K. Kutty (Subang Jaya Medical Centre,P.J.) for the interesting and enlightening pathological guidance.

Many thanks to Uma for her editorial assistance and Linda for typing this thesis.

I would also like to thank all my friends, especially at the Molecular Biology Lab (B503), Institute for Advanced Studies (Rakesh, Geetha, Lin, Selva, Sudeep, Raj, Meena, Ahila, Brendan, Ashril, and Moh Hoong) for their support and friendship. Very special thanks to Yati, Vimala and Nirmala for their very special and unique friendship.

To Vimi, for being a dear friend and for many interesting moments,a special thanks. Last but not least, my humble gratitude to my parents for their constant support, guidance and love through all my endeavors.

# List of Contents

|  | Page   |
|--|--------|
| Abstract   | (i)    |
| Acknowledgment   | (iv)   |
| List of contents   | (v)    |
| List of Abbreviations  | (x)    |
| List Figures   | (xiii) |
| List of Tables   | (xvi)  |
| <br>CHAPTER 1 : INTRODUCTION                                     |        |
| <br>CHAPTER 2 : LITERATURE REVIEW                                |        |
| 2.1 Ultrastructure of HHV-6                                      | 7      |
| 2.2 Growth properties of HHV-6                                   | 7      |
| 2.3 Target Cells of Infection                                    | 9      |
| 2.4 Molecular biology of HHV-6                                   | 13     |
| 2.5 Protein and Protein expression of HHV-6                      | 16     |
| 2.6 Interstrain molecular heterogeneity                          | 20     |
| 2.7 Seroepidemiology of HHV-6                                    | 25     |
| 2.8 Viral transmission   | 28     |
| 2.9 Clinical pathology of HHV-6                                  | 31     |
| 2.9.1 HHV-6 and exanthem subitum                                 | 31     |
| 2.9.2 HHV-6 associated infectious mononucleosis                  | 34     |
| 2.9.3 HHV-6 in Immune disorders and lymphoproliferative diseases | 34     |
| 2.9.4 HHV-6 and Human-Immunodeficiency virus infection           | 35     |
| 1. HHV-6 reactivation in organ transplantation                   | 37     |

|        |   |    |
|--------|---|----|
| 2.9.6  | HHV-6 and chronic fatigue syndrome          | 38 |
| 2.9.7  | HHV-6 and necrotising lymphadenitis         | 39 |
| 2.10   | Diagnostic tools for the detection of HHV-6 | 39 |
| 2.10.1 | Polymerase Chain Reaction                   | 41 |
| 2.10.2 | Immunohistochemistry                        | 50 |

### CHAPTER 3 : MATERIALS AND METHODS

|        |  |    |
|--------|--|----|
| 3.1    | Source of DNA and techniques   | 52 |
| 3.2    | Blood samples  | 52 |
| 3.3    | Fresh frozen tissue  | 52 |
| 3.4    | Paraffin-embedded tissues  | 53 |
| 3.5    | Primers used in this study   | 53 |
| 3.6    | Probes used in the study   | 54 |
| 3.7    | Monoclonal antibody used   | 55 |
| 3.8    | Extraction of DNA from blood   | 55 |
| 3.9    | Extraction of DNA from fresh frozen tissue                             | 56 |
| 3.10   | Extraction of DNA from formalin-fixed and paraffin<br>embedded tissues | 57 |
| 3.11   | Preparation of HHV-6 DNA probe   | 58 |
| 3.11.1 | Culturing of <i>E. coli</i> containing the pZVH14 clone                | 58 |
| 3.11.2 | Plasmid extraction   | 58 |
| 3.12   | Quantification of DNA  | 59 |
| 3.13   | Polymerase Chain Reaction (PCR)  | 59 |
| 3.13.1 | Direct PCR with A and B primers  | 60 |
| 3.13.2 | Nested PCR   | 61 |
| 3.14   | Agarose gel electrophoresis  | 63 |

|   | Page |
|---|------|
| 3.15 DNA Probe labeling   | 64   |
| 3.16 Southern transfer and hybridization of PCR amplified products                        | 65   |
| 3.16.1 Non-radioactive hybridization  | 66   |
| 3.16.2 Detection of hybridization signals   | 67   |
| 3.17 Cell culture techniques  | 68   |
| 3.17.1 Revival of cells   | 68   |
| 3.17.2 Maintenance of cultures  | 68   |
| 3.17.3 Cryopreservation of cells  | 69   |
| 3.17.4 Infection of HSB-2 cells with HHV-6 (GS)   | 69   |
| 3.17.5 Harvesting of cells  | 70   |
| 3.18 Immunohistochemistry : Antigen expression studies                                    | 70   |
| 3.18.1 Pretreatment of slides   | 70   |
| 3.18.2 Immunohistochemical staining for HHV-6 antigens                                    | 71   |
| 3.19 Viral adsorption studies   | 72   |
| 3.20 Hematoxylin and Eosin (H+E) staining   | 72   |
| <br><b>CHAPTER 4 : RESULTS</b>  |      |
| 4.0 Optimization of PCR and hybridization techniques                                      | 74   |
| 4.1 Prevalence of HHV-6 in DNA extracted from patients with leukemia and lymphoma tissues | 75   |
| 4.1.1 Clinical parameters of the patients   | 75   |
| 4.1.2 Amplification with A and B primers  | 76   |
| 4.1.3. Amplification with outer (P0 and P4) and nested (P1 and P3) primers                | 77   |
| 4.1.4 Southern hybridization of PCR products with probe S                                 | 77   |
| 4.1.5 Southern hybridization of PCR products with probe P2                                | 78   |

|  | <b>Page</b> |
|--|-------------|
| 4.2. Prevalence of HHV-6 in DNA extracted from oral carcinoma and precancerous lesions | 86          |
| 4.2.1 Clinical parameters of patients  | 86          |
| 4.2.2 Amplification with A and B primers   | 87          |
| 4.2.3 Amplification with outer (P0 and P4) primers and nested (P1 and P3) primers      | 87          |
| 4.2.4 Southern hybridization of amplified products with probe S                        | 88          |
| 4.2.5 Southern hybridization of amplified products with probe P2                       | 88          |
| 4.2.6 Dot blot of genomic (unamplified) DNA of oral tissue                             | 89          |
| 4.3 Prevalence of HHV-6 in DNA extracted from cervical carcinoma                       | 96          |
| 4.3.1 Clinical parameters of patients  | 96          |
| 4.3.2 Amplification with A and B primers   | 96          |
| 4.3.3 Amplification with outer (P0 and P4) primers and nested (P1 and P3) primers      | 96          |
| 4.3.4 Southern hybridization of amplified products with probe S                        | 96          |
| 4.3.5 Southern hybridization of amplified products with probe P2                       | 97          |
| 4.4. Monoclonal antibody reactivity to HHV-6 in oral lesions                           | 105         |
| 4.5 Monoclonal antibody reactivity to HHV-6 in cervical lesions                        | 111         |
| <br><b>CHAPTER 5 : DISCUSSION</b>  |             |
| 5.1 Molecular detection methods of HHV-6   | 121         |

|   | <b>Page</b>    |
|---|----------------|
| 5.1.1 Polymerase Chain Reaction (PCR) and non-radioactive hybridization of amplified products | 121            |
| 5.1.2 Immunohistochemistry  | 127            |
| 5.2 Detection of HHV-6 in leukemia and lymphoma tissues                                       | 127            |
| 5.2.1 Detection of HHV-6 in leukemia  | 127            |
| 5.2.2 Detection of HHV-6 in lymphoma  | 133            |
| 5.3 Detection of HHV-6 in oral carcinoma and pre-cancer lesions                               | 137            |
| 5.3.1 Detection of HHV-6 in squamous cell carcinoma of the buccal mucosa                      | 137            |
| 5.3.2 Detection of HHV-6 in pre-cancer oral lesions   | 144            |
| 5.4 Detection of HHV-6 in cervical carcinoma and pre-cancer lesions                           | 146            |
| 5.5 Conclusion  | 148            |
| <br><b>REFERENCE</b>  | <br><b>149</b> |
| <br><b>APPENDIX: A. Solutions</b>   | <br><b>187</b> |
| <b>B. Publication</b>   | <b>197</b>     |



## List of Abbreviations

|                    |   |
|--------------------|---|
| %                  | : percentage                                |
| ACIF               | : Anti Complement Immunofluorescence Assay  |
| AIDS               | : Acquired Immunodeficiency Syndrome        |
| ALL                | : Acute lymphocytic leukemia                |
| Asense             | : anti sense                                |
| AML                | : Acute myeloid leukemia                    |
| AUL                | : Acute undifferentiated leukemia           |
| BCIP               | : 5-bromo-4-chloro-3-indoyl-phosphate       |
| BL                 | : Burkitt's lymphoma                        |
| bp                 | : base pair                                 |
| CBL                | : cord blood lymphocytes                    |
| CFS                | : Chronic Fatigue Syndrome                  |
| CIN3               | : Cervical intraepithelial neoplasm-grade 3 |
| CIS                | : Carcinoma <i>in situ</i>                  |
| cm                 | : centimetre                                |
| CML                | : Chronic myeloid leukemia                  |
| CMV                | : Cytomegalovirus                           |
| dATP               | : deoxyadenosine triphosphate               |
| dCTP               | : deoxycytidine triphosphate                |
| dGTP               | : deoxyguanosine triphosphate               |
| ddH <sub>2</sub> O | : deionized distilled water                 |
| dig                | : digoxigenin                               |
| DNA                | : Deoxyribonuclease                         |
| dNTP               | : deoxynucleotide triphosphate              |

|                         |  |
|-------------------------|--|
| <b>dTTP</b>             | : deoxythymidine triphosphate                |
| <b>EBV</b>              | : Epstein-Barr virus                         |
| <b>EDTA</b>             | : ethylenediamine tetraacetic acid           |
| <b>ELISA</b>            | : Enzyme-linked immunosorbent assay          |
| <b>gm</b>               | : gram                                       |
| <b>H &amp; E</b>        | : Hematoxylin and Eosinofil                  |
| <b>HCl</b>              | : hydrochloric acid                          |
| <b>HEPES</b>            | : hydroxyethylpiperazine ethanesulfonic acid |
| <b>HIV</b>              | : Human Immunodeficiency virus               |
| <b>HL</b>               | : Hodgkin's lymphoma                         |
| <b>HSV</b>              | : Herpes Simplex virus                       |
| <b>HTLV</b>             | : Human T-leukemia virus                     |
| <b>IFA</b>              | : Immunofluorescence Assay                   |
| <b>KAc</b>              | : potassium acetate                          |
| <b>kb</b>               | : Kilobase                                   |
| <b>KCl</b>              | : potassium chloride                         |
| <b>LTP</b>              | : large tegument protein                     |
| <b>LTR</b>              | : long terminal repeat                       |
| <b>μ</b>                | : micron                                     |
| <b>M</b>                | : molar                                      |
| <b>MA</b>               | : membrane antigen                           |
| <b>Mab</b>              | : Monoclonal antibody                        |
| <b>μg</b>               | : microgram                                  |
| <b>mg</b>               | : milligram                                  |
| <b>MgCl<sub>2</sub></b> | : magnesium chloride                         |
| <b>μl</b>               | : microlitre                                 |

|              |          |  |
|--------------|----------|--|
| <b>ml</b>    | <b>:</b> | <b>millilitre</b>                          |
| <b>μm</b>    | <b>:</b> | <b>micrometre</b>                          |
| <b>MOPS</b>  | <b>:</b> | <b>3-N-morpholino-propanesulfonic acid</b> |
| <b>NaCl</b>  | <b>:</b> | <b>sodium chloride</b>                     |
| <b>NaOH</b>  | <b>:</b> | <b>sodium hydroxide</b>                    |
| <b>NBT</b>   | <b>:</b> | <b>4-nitro blue tetrazolium chloride</b>   |
| <b>ng</b>    | <b>:</b> | <b>nanogram</b>                            |
| <b>NHL</b>   | <b>:</b> | <b>non-Hodgkin's lymphoma</b>              |
| <b>nm</b>    | <b>:</b> | <b>nanometer</b>                           |
| <b>NPC</b>   | <b>:</b> | <b>Nasopharyngeal Carcinoma</b>            |
| <b>°C</b>    | <b>:</b> | <b>degree centigrade</b>                   |
| <b>PBMC</b>  | <b>:</b> | <b>peripheral blood mononuclear cells</b>  |
| <b>PBS</b>   | <b>:</b> | <b>phosphate buffered saline</b>           |
| <b>psi</b>   | <b>:</b> | <b>pounds per square inch</b>              |
| <b>RNase</b> | <b>:</b> | <b>ribonuclease</b>                        |
| <b>rpm</b>   | <b>:</b> | <b>revolutions per minute</b>              |
| <b>SCC</b>   | <b>:</b> | <b>squamous cell carcinoma</b>             |
| <b>SDS</b>   | <b>:</b> | <b>sodium dodecyl sulphate</b>             |
| <b>TBE</b>   | <b>:</b> | <b>tris-borate-EDTA</b>                    |
| <b>Tris</b>  | <b>:</b> | <b>trisma base</b>                         |
| <b>U</b>     | <b>:</b> | <b>units</b>                               |
| <b>UV</b>    | <b>:</b> | <b>ultraviolet</b>                         |
| <b>VCA</b>   | <b>:</b> | <b>viral capsid antigen</b>                |
| <b>VZV</b>   | <b>:</b> | <b>Varicella-Zoster virus</b>              |
| <b>w/v</b>   | <b>:</b> | <b>weight per volume</b>                   |
| <b>WHO</b>   | <b>:</b> | <b>World Health Organization</b>           |

## List of Figures

|  | Page |
|--|------|
| Fig. 2.1 : Schematic representation of the HHV-6 overall genomic structure   | 15   |
| Fig. 2.2 : Restriction map of the U1102 HHV-6 genome   | 17   |
| Fig. 2.3 : Partial nucleotide sequences of amplified DNA fragments from strains SIE and HST  | 26   |
| Fig. 2.4 : The replication cycle of HHV-6 in CD4-positive lymphocytes  | 30   |
| Fig. 2.5 : The development of exanthem subitum in a 6-month old baby showing the duration of skin rashes coincide with the appearance of antibody to HHV-6 | 33   |
| Fig. 4.1 : 2% Agarose gel showing PCR amplified DNA with A and B primers   | 101  |
| Fig. 4.2 : 2% Agarose gel showing PCR amplified DNA with nested primers (P1 and P3)  | 102  |
| Fig. 4.3 : Southern hybridization of PCR amplified products (A and B primers) to S probe   | 103  |
| Fig. 4.4 : Southern hybridization of PCR amplified products (P1 and P3 primers) to P2 probe  | 104  |
| Fig. 4.5 : HHV-6 infected HSB-2 cells exhibiting intense intracytoplasmic staining to HHV-6 monoclonal antibody GA5G3                                      | 112  |
| Fig. 4.6 : Uninfected HSB-2 cells showing no staining to HHV-6 monoclonal antibody GA5G3 as a negative control   | 112  |

|                   |   |            |
|-------------------|---|------------|
| <b>Fig. 4.7a</b>  | <b>: Intense nuclear and cytoplasmic reactivity in malignant cells to HHV-6 Mab in a well differentiated squamous cells carcinoma</b> | <b>113</b> |
| <b>Fig. 4.7b</b>  | <b>: Membrane staining in malignant cells to HHV-6 Mab in a well differentiated squamous cell carcinoma</b>                           | <b>113</b> |
| <b>Fig. 4.8a</b>  | <b>: H+E staining of a poorly differentiated squamous cell carcinoma of the buccal mucosa</b>   | <b>114</b> |
| <b>Fig. 4.8b</b>  | <b>: Intense HHV-6 Mab staining in a poorly differentiated cell carcinoma of the buccal mucosa</b>                                    | <b>114</b> |
| <b>Fig. 4.9a</b>  | <b>: H+E staining of a moderately differentiated squamous cell carcinoma of the buccal mucosa</b>                                     | <b>115</b> |
| <b>Fig. 4.9b</b>  | <b>: Intense HHV-6 Mab staining of a moderately differentiated squamous cell carcinoma of the buccal mucosa</b>                       | <b>115</b> |
| <b>Fig 4.10a</b>  | <b>: H+E staining of a well differentiated keratinizing squamous cell carcinoma of the buccal mucosa</b>                              | <b>116</b> |
| <b>Fig. 4.10b</b> | <b>: Intense HHV-6 Mab staining in a well differentiated keratinizing squamous cell carcinoma of the buccal mucosa</b>                | <b>116</b> |
| <b>Fig. 4.11a</b> | <b>: H+E staining of a lichen planus lesion of the buccal mucosa</b>  | <b>117</b> |
| <b>Fig. 4.11b</b> | <b>: Intense HHV-6 Mab staining in a lichen planus lesion of the buccal mucosa</b>  | <b>117</b> |
| <b>Fig. 4.12a</b> | <b>: H+E staining of a leukoplakia lesion of the buccal mucosa</b>  | <b>118</b> |

**Fig. 4.12b : Intense HHV-6 Mab staining in a leukoplakia lesion 118**

**Fig. 4.13 : Cytokeratin reactivity in a well differentiated 119**  
**squamous cell carcinoma of the buccal mucosa**

**Fig. 4.14a : Immunostaining of an oral carcinoma tissue 120**  
**section with Mab to HHV-6 (well differentiated, SCC)**

**Fig. 4.14b : Immunostaining following the adsorption of the 120**  
**monoclonal antibody to viral particles**

## List of Tables

|  | Page |
|--|------|
| Table 1.1 : Reports of HHV-6 isolation   | 5    |
| Table 1.2 : Human herpesviruses and their general<br>antibody prevalence in human populations                        | 6    |
| Table 2.1 : HHV-6 isolates reported to grow in T cell lines  | 10   |
| Table 2.2 : Categorization of different HHV-6 strains using<br>restriction analysis polymorphisms                    | 22   |
| Table 2.3 : Infection of human cells <i>in vitro</i> with various<br>HHV-6 isolates                                  | 23   |
| Table 2.4 : Reactivities of various HHV-6 isolates to<br>monoclonal antibodies against GS isolate by<br>indirect IFA | 24   |
| Table 2.5 : Antibody prevalence and titre to HHV-6 in some<br>disease  | 27   |
| Table 2.6 : Detection by PCR of HHV-6 genome in healthy<br>individuals   | 46   |
| Table 2.7 : Detection by PCR of HHV-6 in disease   | 47   |
| Table 2.8 : Some HHV-6 specific primer sequences   | 49   |
| Table 3.1 : Primers used in the study  | 54   |
| Table 3.2 : Reaction mix amplifying HHV-6 sequence with<br>A and B primers.  | 60   |
| Table 3.3 : Amplification with external primers P0 and P4  | 61   |
| Table 3.4 : Amplification with internal (nested) primers,<br>P1 and P3   | 62   |

|             |   |    |
|-------------|---|----|
| Table 4.1   | : Distribution of leukemia and lymphoma patients by race  | 79 |
| Table 4.2   | : Distribution of leukemia and lymphoma patients by age, sex and disease  | 80 |
| Table 4.3.1 | : PCR amplification of HHV-6 DNA to two different primer sets in patients with leukemia                         | 81 |
| Table 4.3.2 | : PCR amplification of HHV-6 DNA to two different primer sets in patients with various lymphomas                | 81 |
| Table 4.4.1 | : Southern hybridization of amplified DNA products with two different probes in patients with leukemia          | 82 |
| Table 4.4.2 | : Southern hybridization of amplified DNA products with two different probes in patients with lymphomas         | 82 |
| Table 4.5   | : Details of patients with leukemia and lymphoma and results of PCR   | 83 |
| Table 4.6   | : Distribution of oral cancer (SCC) and pre-cancer lesion patients by race                                      | 90 |
| Table 4.7   | : Distribution of oral cancer (SCC) and pre-cancer lesion patients by age, sex and disease                      | 91 |
| Table 4.8.1 | : PCR amplification of HHV-6 DNA to two different primer sets in patients with oral cancer (SCC)                | 92 |
| Table 4.8.2 | : PCR amplification of HHV-6 DNA to two different primer sets in patient with pre-cancer lesions                | 92 |
| Table 4.9.1 | : Southern hybridization of amplified DNA products with two different probes in patients with oral cancer (SCC) | 93 |



|                      |   |            |
|----------------------|---|------------|
| <b>Table 4.9.2 :</b> | <b>Southern hybridization of amplified DNA products with two different probes in patients with pre-cancer lesions</b> | <b>93</b>  |
| <b>Table 4.10 :</b>  | <b>Details of patients with oral cancer and pre-cancer lesions and results of PCR</b>                                 | <b>94</b>  |
| <b>Table 4.11 :</b>  | <b>Distribution of Cervical Carcinoma patients by race</b>  | <b>98</b>  |
| <b>Table 4.12 :</b>  | <b>Distribution of Cervical Carcinoma patients by age</b>   | <b>98</b>  |
| <b>Table 4.13 :</b>  | <b>PCR amplification of HHV-6 DNA to two different primer sets in patients with Cervical Carcinoma</b>                | <b>99</b>  |
| <b>Table 4.14 :</b>  | <b>Southern hybridization of amplified DNA products with two different probes in patients with Cervical Carcinoma</b> | <b>99</b>  |
| <b>Table 4.15 :</b>  | <b>Details of patients with Cervical Carcinoma and results of PCR</b>   | <b>100</b> |
| <b>Table 4.16 :</b>  | <b>Mab staining of HHV-6 in patients with Oral Cancer (SCC)</b>   | <b>107</b> |
| <b>Table 4.17 :</b>  | <b>Mab staining of HHV-6 in patients with pre-cancer lesions</b>  | <b>107</b> |
| <b>Table 4.18 :</b>  | <b>Histopathological breakdown of SCC, IMR, K.L.</b>  | <b>108</b> |
| <b>Table 4.19 :</b>  | <b>Details of patients with oral cancer and pre-cancer lesions and results of immunohistochemistry experiment</b>     | <b>110</b> |